Herceptin Hylecta
| Herceptin Hylecta | |
|---|---|
| Term | Herceptin Hylecta |
| Short definition | Herceptin Hylecta (her-SEP-tin hy-LEK-tuh) A combination of trastuzumab and hyaluronidase used alone or with other medicines to treat adults with certain types of HER2-positive breast cancer is applied. Trastuzumab attaches to a protein called HER2, which is found on some cancer cells. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
Herceptin Hylecta - (pronounced) (her-SEP-tin hy-LEK-tuh) A combination of trastuzumab and hyaluronidase used alone or with other medicines to treat adults with certain types of HER2-positive breast cancer is applied. Trastuzumab attaches to a protein called HER2, which is found on some cancer cells. This can help the immune system kill cancer cells. Hyaluronidase allows trastuzumab to be injected under the skin. Herceptin Hylecta can be administered in less time than trastuzumab alone, which is given as an infusion. Also called trastuzumab and hyaluronidase
External links
- Medical encyclopedia article on Herceptin Hylecta
- Wikipedia's article - Herceptin Hylecta
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski